Meta-analysis of androgen deprivation therapy for prostate cancer related with diabetes / 药物评价研究

ABSTRACT

Objective To examine whether androgen deprivation therapy (ADT) is associated with increased risk of diabetes in men with prostate cancer (Pca).Methods The study data were systematically searched from Medline,Embase,and Cochrane Library Central Register.Studies comparing ADT vs control aimed at treating Pca,reporting diabetes as outcome were included.Results Eight studies met inclusion criteria with a total of 65 695 ADT users and 91 893 non-ADT users investigating the relationship between ADT and diabetes.The incidence of diabetes was 39％ higher in ADT groups,and significant association was observed in overall analysis [RR =1.39,95％CI(1.27-1.53),P ＜ 0.01].In subgroup-analyses stratified by ADT types,diabetes was found to be significantly associated with gonadotropin-releasing hormone (GnRH) alone [RR =1.45,95％CI(1.36-1.54),P ＜ 0.01),GnRH plus oral anti-androgen (AA) [RR =1.40,95％CI(1.01-1.93),P ＜ 0.01] and Orchiectomy [RR =1.34,95％CI(1.20-1.50),P ＜ 0.01],but not with AA alone [RR =1.33,95％CI(0.75-2.36),P =0.33].Conclusions ADT,especially GnRH alone,GnRH plus AA and orchiectomy can increase the incidence of diabetes in patients with Pca.